Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PROFILE: Novo's Riis Recalls First Victoza Delivery, Growing Up With Science

This article was originally published in Scrip

Executive Summary

Jakob Riis is a Danish national who joined diabetes R&D giant Novo Nordisk in 1996 as a health economist. He has since risen through the company, via a series of marketing roles of increasing seniority, to take on his current position of executive vice-president of China, Pacific and marketing.

You may also be interested in...



Spring Break: Novo's US Head Resigns After Rough Winter

Novo Nordisk's executive VP and head of North American operations, Jakob Riis, has resigned from the company – a move not completely out of the blue considering recent rumors of conflict within the diabetes drug developer's US operations and a lackluster 2016 financial performance for the whole group.

In Vivo’s Deals Of The Year 2020: Winners Revealed

For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

Direct To Consumer Approach Underscores Femtech’s Disruptive Potential

A new technology accelerator, FemTech Lab, will support the scale-up of at least 10 firms in 2021 that have innovative solutions for issues affecting women’s health and wellbeing. The founders talk to In Vivo about their view of the femtech market and how it will impact traditional health care.

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel